Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.726 USD | -4.47% | +18.16% | -47.06% |
Apr. 09 | Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT | CI |
Apr. 08 | Declaration of Voting Results by Seres Therapeutics | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.06% | 115M | |
-1.44% | 105B | |
+3.86% | 97.5B | |
+1.89% | 22.19B | |
-16.01% | 21.33B | |
-8.17% | 18.68B | |
-42.33% | 16.6B | |
-20.37% | 14.52B | |
+5.87% | 14.09B | |
+21.80% | 10.99B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Seres Therapeutics : Names David Arkowitz Chief Financial Officer